Business
Chimeric IPO: What ASX stockspert Bhavdip143 likes so much about the $35m CAR T play – Stockhead
Institutional investors have queued up to buy stock in Chimeric’s IPO ‘CAR T cell therapy is one of the hottest areas in biotech’ ASX stocks commentator Bhavdip143…
Link copied toclipboard
- Institutional investors have queued up to buy stock in Chimeric’s IPO
- ‘CAR T cell therapy is one of the hottest areas in biotech’ ASX stocks commentator Bhavdip143
- IPO for $35m will fully fund stage one and two clinical trials for CAR T cell treatment
CAR T cell treatment company Chimeric Therapeutics (ASX:CHM) is understood to have easily achieved its IPO fundraising target of $35m ahead of its ASX listing timed for Monday.
Institutional investors have expressed strong interest…
Continue Reading
-
General11 hours agoAustralia’s security abandoned to the folly of declining US empire
-
Noosa News8 hours agoThe systemic failings that allowed paedophile Ashley Paul Griffith to continue working in childcare
-
Noosa News10 hours agoThe shock suburban street fuelling a buyer waiting list
-
General20 hours agoRoger Rasheed slams ‘battle of the sexes’ tennis clash between Nick Kyrgios and Aryna Sabalenka